HIGHBuilt-inProduct / Revenue mix
diagnostic test reports
“10-K Item 1: 'Substantially all of our revenue for the year ended December 31, 2025 was derived from diagnostic test reports'”
WGS · Concentration risk · 10-K extracted
GeneDx Holdings (WGS) concentration risks
Updated
The most significant concentration GeneDx Holdings discloses is diagnostic test reports, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: GeneDx Holdings’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
single suppliers for laboratory instruments and materials
“10-K Item 1A: 'We rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile combines a product-line dependency and a supply-chain vulnerability, both of which are high-share by disclosed size. Substantially all revenue for the year ended December 31, 2025 was derived from diagnostic test reports — a high-share, structural product concentration reflecting the company's singular focus on genomic diagnostics as its commercial model. The structural character means this concentration is inherent to the business rather than a contractual dependency on any individual customer; however, it does mean that any adverse shift in reimbursement policy, regulatory standards for genomic testing, or competitive displacement in the diagnostics market would affect substantially the entire revenue base simultaneously. On the supply side, the company relies on a limited number of suppliers, or in some cases single suppliers, for some of its laboratory instruments and materials — a high-share, dependency exposure. Sole-source laboratory supply relationships are particularly sensitive in diagnostics because reagents, instruments, and proprietary consumables often require regulatory clearance for specific configurations, making qualification of alternative suppliers time-consuming and operationally disruptive if a primary supplier experiences capacity or quality issues. The two exposures are complementary rather than offsetting: supply chain disruptions in laboratory instruments or materials directly affect the company's ability to generate diagnostic test reports, meaning both high-share concentrations are linked through the same operational pathway. On balance, reimbursement trends for genomic diagnostics and the stability of key supplier relationships are the primary monitoring variables for this name.
For the engine’s reasoning on WGS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Diagnostics & Research
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ADPT | Adaptive Biotechnologies Corpor | 2 | 0 | 0 | 2 |
| WGS● | GeneDx Holdings Corp. | 2 | 0 | 0 | 2 |
| CRL | Charles River Laboratories Inte | 1 | 1 | 0 | 2 |
| BLLN | BillionToOne, Inc. | 1 | 0 | 0 | 1 |
| A | Agilent Technologies, Inc. | 0 | 1 | 0 | 1 |
| DGX | Quest Diagnostics Incorporated | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.